Keyword: ASCO

Gearing up for the year's largest cancer confab, we break down the highlights to give you a glimpse of the studies we’re tracking, so you can follow along, too.

When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.

At last year’s ASCO, AstraZeneca posted Lynparza data that would win the class' first breast cancer nod. Now it’s aiming for prostate cancer.

Merck spent on-stage ASCO time with new Keytruda data, but behind the scenes, it huddled with teams from its big new partners, AstraZeneca and Eisai.

Merck’s Keytruda has a solo OK for first-line lung cancer patients whose tumors bear high levels of PD-L1. But that group will likely soon get bigger.

At this year's ASCO, squamous lung cancer has elbowed nonsquamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight.

Despite some trial setbacks, Bristol-Myers' Opdivo still leads the I-O pack by U.S. revenue. But wins for rival Keytruda could change that soon.

Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.

Today, we’re bringing you the choicest quotes we collected from interviews over ASCO weekend.

If Bristol-Myers Squibb needed more evidence to suggest it had lost the immuno-oncology lead to Merck & Co., it got it at ASCO.